Metabolic and Prolonged Satiety Effects of a Breakfast Kit

Study Overview
=================
Brief Summary
-----------------
The mobilizing programme MobFood - mobilizing scientific knoweledge and technology to answer the current nutrition market challenges - is formed by a consortium of 47 collaborative entities, between the industry and ENESIIs (Entidades Não Empresariais do Sistema de Investigação e Inovação) and is financed by Structural European Funds of Investment. The project is currently investigating and undertaking collaborative scientific and technological strategies based on R&D and innovation, in order to boost and promote a more competitive national food industry, capable of overcoming the current challenges, including those of the Millennial Generation. This group is particularly conscious of the impact of food behaviour and food choices on health but extremely vulnerable to dietary imbalance. Strategies to improve Millenials' nutrition while providing conscious food products are needed. This study is a randomised, cross-over controlled trial designed to test the metabolic effect, particularly in terms of appetite control and glycaemic response of a breakfast kit (nutritionally balanced and innovative), recently developed as part of the collaborative project MobFood_PPS4.

Official Title
-----------------
Metabolic and Prolonged Satiety Effects of a Breakfast Kit: a Randomized Controlled Trial

Conditions
-----------------
Diet Habit

Intervention / Treatment
-----------------
* Other: MobFood breakfast kit
* Other: Control isocaloric breakfast


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female; Born between 1981 and 1996; Body mass index (BMI) between 18.5 kg/m2 and 24.9 kg/m2; Normoglycemic according to American Diabetes Association criteria [Fasting Plasma Glucose < 100 mg/dl, 2-h plasma glucose value during a 75 g oral glucose tolerance test (OGTT) < 140 mg/dl)]; Healthy. Exclusion Criteria: Overweight or obese (BMI ≥ 25,0 kg/m2); Recent body weight loss/gain >10%, within previous 3 months; Being on a weight loss/other special diet (e.g. Paleo diet, Atkins diet, flexitarian diet or ketogenic diet), within previous 3 months; Clinically significant illness, including: type 1 or type 2 diabetes; liver disease e.g. cirrhosis; malignancy; pancreatitis or other malabsorption; gastrointestinal disorders e. g. intestinal bowel disorder, celiac disease; previous weight loss surgery e.g. bariatric surgery; chronic respiratory, neurological, psychiatric, musculoskeletal diseases/conditions; diagnosed eating disorders. Individuals who don't regularly consume breakfast; Having taken antibiotics within the 12 weeks prior to beginning the study; Taking other medication that could potentially affect body weight, glucose metabolism and/or appetite (e.g. GLP-1 analogues); Being engaged in competitive sports; Having >14 or >8 (males and females, respectively) alcoholic units/week; misuse of drugs; Having donated blood within one month prior to the beginning of the study; Nut or milk allergy, or other food allergy or intolerance that would compromise compliance with the study protocol; Pregnant or breastfeeding.

Ages Eligible for Study
-----------------
Minimum Age: 23 Years
Maximum Age: 38 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MobFood breakfast kit<br> | Other: MobFood breakfast kit<br>* Cereal biscuit with orange fruit, cheese with fruit preparation and beverage based on oat, milk and mocha (without added sugar), specifically developed for the project MobFood_PPS4.<br>|
| Experimental: Control isocaloric breakfast<br> | Other: Control isocaloric breakfast<br>* White bread, butter and milk.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differences in the incremental area under the curve (iAUC, mg/dl*min) for glucose response between the 2 arms | The iAUC for glucose will be calculated based on the concentration curve following consumption of the test and control products, over 2h | at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1) | 
| Differences in the iAUC (pmol/l*min) for glucagon-like peptide-1 (GLP-1) between the 2 arms | The iAUC for GLP-1 will be calculated based on the concentration curve following consumption of the test and control products, over 3h | at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1) | 
| Differences in the iAUC (pmol/l*min) for peptide YY (PYY) between the 2 arms | The iAUC for PYY will be calculated based on the concentration curve following consumption of the test and control products, over 3h | at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1) | 
| Differences in the iAUC (pmol/l*min) for cholecystokinin (CKK) between the 2 arms | The iAUC for CKK will be calculated based on the concentration curve following consumption of the test and control products, over 3h | at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1) | 
| Differences in the iAUC (pmol/l*min) for ghrelin between the 2 arms | The iAUC for ghrelin will be calculated based on the concentration curve following consumption of test and control products, over 3h | at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1) | 
| Differences in the iAUC (pmol/l*min) for glucagon between the 2 arms | The iAUC for glucagon will be calculated based on the concentration curve following consumption of the test and control products, over 3h | at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differences in the iAUC (mg/dl*min) for triacylglycerides (TG) between 2 arms | The iAUC for TG will be calculated based on the concentration curve following consumption of the test and control products, over 3h | at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1) | 
| Differences in the iAUC for (mmol/l*min) non-esterified fatty acids (NEFA) between 2 arms | The iAUC for NEFA will be calculated based on the concentration curve following consumption of the test and control products, over 3h | at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1) | 
| Differences in subjective feelings of hunger/satiety between the 2 arms | Difference in subjective feelings of hunger/satiety from fasting state to post-prandial state with the consumption of the test and control products | at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1) |